Cargando…
210. Neutropenia and Associated Infectious Complications Among Kidney Transplant Recipients Receiving Valganciclovir Prophylaxis in the United States: An Administrative Claims Database Study
BACKGROUND: Valganciclovir (VGCV) prophylaxis is commonly utilized to prevent cytomegalovirus (CMV) infection among high (D+/R-) and intermediate (R+) risk kidney transplant recipients (KTRs). Due to the myelosuppressive effects of VGCV, KTRs may be at an increased risk of opportunistic infections (...
Autores principales: | Turzhitsky, Vladimir, Raval, Amit D, Moise, Pamela, Merchant, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752229/ http://dx.doi.org/10.1093/ofid/ofac492.287 |
Ejemplares similares
-
207. Burden of Post-Transplant Neutropenia and Leukopenia among Kidney Transplant Recipients: A Multi-Institutional Real-World Observational Study
por: Raval, Amit D, et al.
Publicado: (2022) -
Mycophenolate-mofetil/valganciclovir: Neutropenia: case report
Publicado: (2022) -
Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022) -
2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023) -
1380. Real-world Effectiveness and Complications of Valganciclovir (VGC) Prophylaxis for Kidney Transplant (KT) Recipients at High Risk for Cytomegalovirus (CMV) infection (CMV Donor (D)+/Recipient (R)-)
por: Roumpz, Caroline G, et al.
Publicado: (2021)